SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(O'Hare Michael) "

Sökning: WFRF:(O'Hare Michael)

  • Resultat 11-12 av 12
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
11.
  • Rossi, Rosanna, et al. (författare)
  • Does prior administration of rtPA influence acute ischemic stroke clot composition? Findings from the analysis of clots retrieved with mechanical thrombectomy from the RESTORE registry.
  • 2022
  • Ingår i: Journal of neurology. - : Springer Science and Business Media LLC. - 1432-1459 .- 0340-5354. ; 269:4, s. 1913-1920
  • Tidskriftsartikel (refereegranskat)abstract
    • There is still much debate whether bridging-therapy [intravenous thrombolysis (IVT) prior to mechanical thrombectomy (MT)] might be beneficial compared to MT alone. We investigated the effect of IVT on size and histological composition of the clots retrieved from patients undergoing bridging-therapy or MT alone.We collected mechanically extracted thrombi from 1000 acute ischemic stroke (AIS) patients included in RESTORE registry. Patients were grouped according to the administration (or not) of IVT before thrombectomy. Gross photos of each clot were taken and Extracted Clot Area (ECA) was measured using ImageJ software. Martius Scarlett Blue stain was used to characterize the main histological clot components [red blood cells (RBCs), fibrin (FIB), platelets/other (PTL)] and Orbit Image Analysis was used for quantification. Additionally, we calculated the area of each main component by multiplying the component percent by ECA. Chi-squared and Kruskal-Wallis tests were used for statistical analysis.451 patients (45%) were treated with bridging-therapy while 549 (55%) underwent MT alone. When considering only percent histological composition, we did not find any difference in RBC% (P=0.895), FIB% (P=0.458) and PTL% (P=0.905). However, bridging-therapy clots were significantly smaller than MT-alone clots [32.7 (14.8-64.9) versus 36.8 (20.1-79.8) mm2, N=1000, H1=7.679, P=0.006*]. A further analysis expressing components per clot area showed that clots retrieved from bridging-therapy cases contained less RBCs [13.25 (4.29-32.06) versus 14.97 (4.93-39.80) mm2, H1=3.637, P=0.056] and significantly less fibrin [9.10 (4.62-17.98) versus 10.54 (5.57-22.48) mm2, H1=7.920, P=0.005*] and platelets/other [5.04 (2.26-11.32) versus 6.54 (2.94-13.79) mm2, H1=9.380, P=0.002*] than MT-alone clots.Our results suggest that previous IVT administration significantly reduces thrombus size, proportionally releasing all the main histological components.
  •  
12.
  • Zabriskie, Matthew S., et al. (författare)
  • BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
  • 2014
  • Ingår i: Cancer Cell. - : Elsevier BV. - 1535-6108 .- 1878-3686. ; 26:3, s. 428-442
  • Tidskriftsartikel (refereegranskat)abstract
    • Ponatinib is the only currently approved tyrosine kinase inhibitor (TKI) that suppresses all BCR-ABL1 single mutants in Philadelphia chromosome-positive (Ph+) leukemia, including the recalcitrant BCR-ABL1(T315I) mutant. However, emergence of compound mutations in a BCR-ABL1 allele may confer ponatinib resistance. We found that clinically reported BCR-ABL1 compound mutants center on 12 key positions and confer varying resistance to imatinib, nilotinib, dasatinib, ponatinib, rebastinib, and bosutinib. T315I-inclusive compound mutants confer high-level resistance to TKIs, including ponatinib. In vitro resistance profiling was predictive of treatment outcomes in Ph+ leukemia patients. Structural explanations for compound mutation-based resistance were obtained through molecular dynamics simulations. Our findings demonstrate that BCR-ABL1 compound mutants confer different levels of TKI resistance, necessitating rational treatment selection to optimize clinical outcome.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 11-12 av 12
Typ av publikation
tidskriftsartikel (10)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (11)
Författare/redaktör
Tatlisumak, Turgut (5)
Rentzos, Alexandros, ... (5)
Brennan, Paul (5)
Douglas, Andrew (5)
Rossi, Rosanna (5)
Fitzgerald, Seán (5)
visa fler...
Pandit, Abhay (5)
McCarthy, Ray (5)
Gilvarry, Michael (5)
Power, Sarah (5)
O'Hare, Alan (5)
Szikora, István (5)
Thornton, John (5)
Redfors, Petra (4)
Jood, Katarina, 1966 (4)
Nagy, Andras (4)
Tsivgoulis, Georgios (4)
Nordanstig, Annika, ... (4)
Ceder, Erik (4)
Dunker, Dennis (4)
Mereuta, Oana Madali ... (4)
Brinjikji, Waleed (3)
Doyle, Karen M (3)
Dehlfors, Niclas (3)
Liu, Yang (2)
Liu, Zhao (2)
Costello, Anthony (2)
Springmann, Marco (2)
Moradi-Lakeh, Maziar (2)
Robinson, Elizabeth ... (2)
Kniveton, Dominic (2)
O'Hare, Michael (2)
Sewe, Maquins Odhiam ... (2)
Nilsson, Maria, 1957 ... (2)
Kallmes, David F. (2)
Gong, Peng (2)
Belesova, Kristine (2)
Otto, Matthias (2)
Wagner, Fabian (2)
Bowen, Kathryn (2)
Graham, Hilary (2)
Sofiev, Mikhail (2)
Ebi, Kristie L. (2)
Hamilton, Ian (2)
Davies, Michael (2)
van Daalen, Kim R. (2)
Semenza, Jan C. (2)
Lowe, Rachel (2)
Kelman, Ilan (2)
Winning, Matthew (2)
visa färre...
Lärosäte
Göteborgs universitet (6)
Karolinska Institutet (3)
Umeå universitet (2)
Uppsala universitet (2)
Linnéuniversitetet (1)
Sveriges Lantbruksuniversitet (1)
Språk
Engelska (12)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (11)
Lantbruksvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy